InspireMD, Inc. (NSPR)
- Previous Close
2.1200 - Open
2.1150 - Bid --
- Ask --
- Day's Range
2.0701 - 2.1500 - 52 Week Range
0.9600 - 3.8500 - Volume
15,830 - Avg. Volume
37,096 - Market Cap (intraday)
49.024M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8200 - Earnings Date May 14, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
www.inspiremd.comRecent News: NSPR
Performance Overview: NSPR
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NSPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NSPR
Valuation Measures
Market Cap
50.22M
Enterprise Value
12.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.37
Price/Book (mrq)
1.27
Enterprise Value/Revenue
2.06
Enterprise Value/EBITDA
-0.61
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.56%
Return on Equity (ttm)
-70.01%
Revenue (ttm)
6.21M
Net Income Avi to Common (ttm)
-19.92M
Diluted EPS (ttm)
-0.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
39.02M
Total Debt/Equity (mrq)
4.04%
Levered Free Cash Flow (ttm)
-9.67M
Research Analysis: NSPR
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell